DLL3 and small cell lung carcinoma: Although initial clinical trials (Phase II TRINITY Study; Phase III TAHOE Study) revealed poor to modest therapeutic effects of DLL3 inhibitor rovalpituzumab tesirine in patients with DLL3-positive SCLC [95,96], recent data with novel DLL3 inhibitors such as tarlatamab appear to be promising [97].